S
Stephen G. Rostand
Researcher at University of Alabama at Birmingham
Publications - 48
Citations - 4669
Stephen G. Rostand is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Kidney disease & End stage renal disease. The author has an hindex of 30, co-authored 48 publications receiving 4505 citations.
Papers
More filters
Journal ArticleDOI
Intensive blood-pressure control in hypertensive chronic kidney disease.
Lawrence J. Appel,Jackson T. Wright,Tom Greene,Lawrence Y. Agodoa,Brad C. Astor,George L. Bakris,William H. Cleveland,Jeanne Charleston,Gabriel Contreras,Marquetta Faulkner,Francis B. Gabbai,Jennifer J. Gassman,Lee A. Hebert,Kenneth Jamerson,Joel D. Kopple,John W. Kusek,James P. Lash,Janice P. Lea,Julia B. Lewis,Michael S. Lipkowitz,Shaul G. Massry,Edgar R. Miller,Keith C. Norris,Robert A. Phillips,Velvie A. Pogue,Otelio S. Randall,Stephen G. Rostand,Miroslaw Smogorzewski,Robert D. Toto,Xuelei Wang +29 more
TL;DR: Overall analyses, intensive blood-pressure control had no effect on kidney disease progression, however, there may be differential effects of intensiveBlood pressure control in patients with and those without baseline proteinuria, as well as according to the baseline level of proteinuria.
Journal ArticleDOI
Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure
TL;DR: The hyperparathyroid state and altered vitamin D status found in Uremia contribute to the cardiovascular pathology seen clinically in uremia and also to the excess mortality from cardiovascular causes found in this patient group.
Journal ArticleDOI
Ultraviolet Light May Contribute to Geographic and Racial Blood Pressure Differences
TL;DR: Reduced epidermal vitamin D3 photosynthesis associated with high skin melanin content and/or decreased UV light intensity at distances from the equator, alone or when coupled with decreased dietary calcium and vitamin D, may be associated with reduced vitamin D stores and increased parathyroid hormone secretion.
Journal ArticleDOI
Racial Differences in the Incidence of Treatment for End-Stage Renal Disease
TL;DR: The number of patients undergoing treatment for end-stage renal disease (ESRD) has increased dramatically since 1973, when Medicare began funding its treatment and is now much greater than the number in the most economically and technologically advanced countries of Europe.
Journal ArticleDOI
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension
Janice P. Lea,Tom Greene,Lee A. Hebert,Michael S. Lipkowitz,Shaul G. Massry,John P. Middleton,Stephen G. Rostand,Edgar R. Miller,Winifred Smith,George L. Bakris +9 more
TL;DR: Baseline proteinuria and GFR predicted the rgate of GFR decline and initial change in proteinuria from baseline to 6 months predicted subsequent progression, with this relationship extending to participants with baseline urinary protein levels less than 300 mg/d.